The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of bevacizumab in metastatic colorectal cancer (mCRC): Pooled analysis from randomized controlled trials (RCTs).
Niall Christopher Tebbutt
Consultant or Advisory Role - Roche (U)
Research Funding - Roche
Herbert Hurwitz
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Roche/Genentech; Sanofi
Honoraria - Roche
Research Funding - Bristol-Myers Squibb; Pfizer; Roche/Genentech; Sanofi
Fairooz Kabbinavar
Honoraria - Roche/Genentech
Bruce J. Giantonio
Honoraria - Roche/Genentech
Zhongzhen Guan
No relevant relationships to disclose
Lada Mitchell
Employment or Leadership Position - Roche
Daniel Waterkamp
Employment or Leadership Position - Roche
Josep Tabernero
Consultant or Advisory Role - Roche/Genentech